CLI.L

CLS Holdings Plc
CLS Holdings PLC - CLS leases over 8,900 sqm in Hamburg, Germany
4th September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 7615C
CLS Holdings PLC
04 September 2024
 

Text Description automatically generatedA red and white gradient with white text Description automatically generated

 

 

 

 

 

 

 

 


 

 

PRESS RELEASE

 

 

Release date:                4 September 2024

Embargoed until:           07:00 am

 

CLS Holdings plc ("CLS" or the "Group")

CLS leases over 8,900 sqm in Hamburg, Germany

 

CLS announces it has let 8,939 sqm (96,219 sq. ft) at Fangdieckstrasse 75 in Hamburg to the Hamburg Institut für Pathologie und Hämatopathologie (HPH).

 

The HPH Institute, which specialises in the diagnosis of haematological diseases, has extended its existing lease of 5,628 sqm (60,579 sq. ft) of office and laboratory space until 2035 and has leased an additional 3,311 sqm (35,639 sq. ft) of office and production space in the property. The HPH Institute will move into the additional space from September 2024, following the current occupier's lease surrender, meaning the property will remain fully let.

 

Fangdieckstrasse 75 was acquired by CLS in 2007 and has since been fully refurbished and successfully repositioned as a science and healthcare hub. The multi-tenant property has 13,092 sqm (140,921 Sq. ft) and offers a mix of office, light industrial, and laboratory space.

 

Located close to the 'Science City Hamburg Bahrenfeld' area of Hamburg, occupied by science and technology start-ups, the property is well connected to major transport links.

 

Fredrik Widlund, Chief Executive Officer of CLS, commented:

 

"We are thrilled that HPH has not only extended their existing lease for over 10 years but has also chosen to lease additional space in Fangdieckstrasse 75. Hamburg-Bahrenfeld is an up-and-coming commercial area and CLS has successfully repositioned the property as an attractive location for science and technology organisations, and demand from occupiers in this sector remains high."

 

-ENDS-

 

 

 

For further information, please contact:

 

CLS Holdings plc

(LEI: 213800A357TKB2TD9U78)

www.clsholdings.com

Fredrik Widlund, Chief Executive Officer

Andrew Kirkman, Chief Financial Officer

+44 (0)20 7582 7766

 

Media Contact:

 

Edelman Smithfield (Financial PR)

Alex Simmons 

+44 7970 174 353

Hastings Tarrant

+44 7813 407 665

cls@edelmansmithfield.com

 

Broker Contacts:

 

Panmure Liberum

Jamie Richards

David Watkins

+44 (0)20 3100 2000

 

Berenberg

Matthew Armitt

Richard Bootle

A picture containing text, emblem, logo, symbol Description automatically generated+44 (0) 203 207 7800

 

Registered in England No. 2714781. Registered Office as above

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUOUVRSAUKRAR]]>
TwitterFacebookLinkedIn